Allogene Therapeutics Price To Book vs. Cash Per Share
| ALLO Stock | USD 1.60 0.08 4.76% |
For Allogene Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Allogene Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Allogene Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Allogene Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Allogene Therapeutics over time as well as its relative position and ranking within its peers.
Allogene |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Allogene Therapeutics Cash Per Share vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Allogene Therapeutics's current stock value. Our valuation model uses many indicators to compare Allogene Therapeutics value to that of its competitors to determine the firm's financial worth. Allogene Therapeutics is rated below average in price to book category among its peers. It also is rated below average in cash per share category among its peers fabricating about 4.14 of Cash Per Share per Price To Book. At this time, Allogene Therapeutics' Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allogene Therapeutics' earnings, one of the primary drivers of an investment's value.Allogene Cash Per Share vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Allogene Therapeutics |
| = | 0.82 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Allogene Therapeutics |
| = | 3.41 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Allogene Cash Per Share Comparison
Allogene Therapeutics is currently under evaluation in cash per share category among its peers.
Allogene Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Allogene Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Allogene Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Allogene Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Allogene Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -89 K | -93.5 K | |
| Operating Income | -273.2 M | -286.9 M | |
| Net Loss | -257.6 M | -270.5 M | |
| Income Before Tax | -257.1 M | -270 M | |
| Total Other Income Expense Net | 16.1 M | 16.9 M | |
| Net Loss | -299.4 M | -314.3 M | |
| Net Loss | -257.6 M | -270.5 M | |
| Income Tax Expense | 443 K | 465.1 K | |
| Net Interest Income | 20 M | 11 M | |
| Interest Income | 20.2 M | 11.6 M | |
| Non Operating Income Net Other | -1.4 M | -1.3 M | |
| Change To Netincome | 84.7 M | 76.9 M | |
| Net Loss | (1.32) | (1.39) | |
| Income Quality | 0.78 | 0.49 | |
| Net Income Per E B T | 0.90 | 0.78 |
Allogene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Allogene Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Allogene Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Allogene Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Allogene Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Use Investing Themes to Complement your Allogene Therapeutics position
In addition to having Allogene Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electrical Equipment Thematic Idea Now
Electrical Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electrical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electrical Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
To fully project Allogene Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Allogene Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Allogene Therapeutics' income statement, its balance sheet, and the statement of cash flows.